Enlivex Therapeutics To Present Late-breaking Poster At ACR Convergence 2025 Featuring Phase IIa Topline Data For Allocetra In Patients With Moderate-To-Severe Knee Osteoarthritis. Data Showed Clinically Meaningful And Statistically Significant Improvements In Pain Reduction And Function Versus Placebo

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois.

The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA), including clinically meaningful and statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function, in idiopathic age-related osteoarthritis patients (≥60 years), representing more than 50% of the total KOA market and 54% of the study population, as well as new supporting biomarker data. The data will be presented by Prof. Philip Conaghan, Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Professor Conaghan is an international leader in osteoarthritis and musculoskeletal imaging, who has authored more than 700 publications and chaired multiple global guidelines and trial initiatives.